BrainCells launches IIa trial after $50M VC round

San Diego-based BrainCells is moving its lead program into a Phase IIa trial after boosting its second venture round with a second tranche. The new money brings its second round to $50 million. BrainCells says it's developing compounds that promote the growth of new neurons for CNS diseases. Its lead product candidate, BCI-540, is designed to treat patients suffering from depression with anxiety.

"Current therapies directly impact serotonin levels causing many unpleasant side effects, however we have shown that BCI-540 directly impacts neurogenesis without affecting serotonin levels," says Carrolee Barlow, M.D., Ph.D., the CSI at BCI.

- check out the press release

Suggested Articles

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.